Our team

Introduction of CEO

CEO

  • 1987

    M.D. Seoul National University College of medicine

  • 1995

    M.D./Ph.D. Graduate School of Medicine, Seoul National University

  • 1998

    Assistant Professor, SNUCM

  • 1999 - 2000

    University of Chicago, USA (Prof. Jeff Bluestone)

  • 2001

    Diabetes Center, UCSF, USA (Prof. Jeff Bluestone)

  • 2004

    Associate Professor, SNUCM

  • 2009 - present

    Professor, SNUCM

  • 2010 - 2012

    Vice President of Research, SNUCM

  • 2012 - 2016

    Head professor, Department of microbiology and immunology, SNUCM

  • 2012 - 2016

    Director, International Xenotransplantation Association (IXA)

  • 2017

    President of the Korean Immunology Association

  • 2016 - present

    Associate editor, Xenotransplantation(Journal)

  • 2017 - present

    Asian Pancreatic/Pancreatic Islet Transplantation Association (Chairman of External Cooperation)

  • 2020 - present

    Editorial board member, Cytokine(Journal)

  • 2021 - present

    PB Immune Therapeutics Co

  • As a basic medical scientist (MD, PhD), he has been devoted to research in the field of immunology for more than 30 years and has published more than 160 papers in SCI journals.
  • Served as president of the Korean Immunology Association, as director of International Xenotransplantation Association, as vice-president of SNU College of Medicine, and as vice-president of the Korean Association for Laboratory Animal Science
  • Awarded the 20th Uidang Academic Award, Myung Ju-wan Medical Award
  • Establishment of Seoul National University Hospital Primate Research Center designated by the Ministry of Health and Welfare (project manager)
  • Head of Xenotransplantation Research Center (supported by the Ministry of Health and Welfare)

Management Team

  • Kun-Sang Park

    CIO

    "Bio value chain operation experience"

    • 1990

      SNUCM M.D

    • 1994

      SNU Hospital Internal Medicine Specialist & Full-time Physician

    • 2001

      Clinical Lecturer, Dept. of Endocrinology, Samsung Seoul Hospital

    • 2020

      SNU Genomics Research Center

    • 2021-present

      PB Immune Therapeutics Co.

  • Jung-Sik Kim

    COO

    "Design and administration of business operations and technology"

    • 2002–2005

      PhD, Seoul National University College of Medicine, Immunology

    • 2006–2013

      Research professor, Seoul National University Hospital

    • 2013-2019

      Research Professor, Seoul National University, College of Medicine

    • 2019-2021

      DiNonA. InC (Kumho HT) CTO, Executive director

    • 2021-present

      PB Immune Therapeutics Co.

  • Hyun-Je Kim

    CTO

    "Introduce the latest immunology research techniques"

    • 2007

      Bachelor of Medicine, SNUCM (Medicine)

    • 2012

      Specialist, Samsung Seoul Hospital (Dermatology)

    • 2017

      Doctor of Medicine, SNU Graduate School of Medicine (Immunology)

    • 2017-2019

      Instructor, Ichan School of Medicine at Mount Sinai

    • 2020

      Samsung Seoul Hospital Dermatology Research Lecturer

    • 2021-present

      Institute of Infectious Diseases, SNUCM

    • 2021-present

      PB Immune Therapeutics Co.

  • Jong-Min Kim

    CDO

    "Rich preclinical experience in primates"

    • 2004

      Bachelor of Veterinary Medicine, Chungbuk National University

    • 2011

      Doctor of Veterinary Medicine, Chungbuk National University

    • 2006-2009

      SNU Hospital Preclinical Experiment Department, Senior Animal Team Leader

    • 2013-present

      Research Assistant Professor, SNU

    • 2021-present

      PB Immune Therapeutics Co.

  • Chang-Ho Lee

    CRDO

    "Extensive experience in research and development of gene therapy"

    • 2005

      B.S., Molecular Biology, Dankook university

    • 2007

      M.S., Molecular Biology, Dankook university

    • 2012

      PhD., Molecular Biology, Dankook university

    • 2012-2021

      Research Professor, Dept. of Molecular biology, Dankook University

    • 2021-2022

      General manager of CMC Team, ANL BIO CO.

    • 2022-present

      PB Immune Therapeutics Co.